The TBE Book: 2nd Edition

Pirmais vāks
Prof. Dr. Gerhard Dobler, Dr. Wilhelm Erber, Dr. Michael Bröker, Prof. Dr. Heinz-Josef Schmit
Global Health Press, 2019. gada 15. apr. - 470 lappuses

While the number of vector-borne diseases and their incidence in Europe is much less than in tropical and/or developing countries, there are nevertheless a substantial number of such infections in Europe. The most important one is the zoonotic arbovirus infection Tick-Borne Encephalitis (TBE), a virus transmitted to humans by ticks or by consumption of unpasteurized dairy products from infected cows, goats, or sheep.


TBE is endemic in the non-tropical Eurasian forest belt with most cases occurring in Russia and in central and eastern parts of Europe. In endemic areas, TBE is one of the most important causes of viral meningitis/encephalitis and a major public health concern. Moreover, TBE is becoming more and more frequent in Europe due to the appearance of new endemic areas and increasing awareness.


However, it might be difficult to diagnose TBE, because clinical manifestations tend to be relatively nonspecific. Although a standardized case definition across the European Union has existed now for a few years, national implementation of TBE programs, including regular screening and diagnosis, are done in only very few countries. Therefore, wide differences in the intensity and quality of national surveillance of TBE cases still exist, and the true burden of disease and the areas with circulation of the TBE viral subtypes in Europe and Asia are not fully known. Moreover, although safe and effective vaccines are available, vaccination uptake in most endemic countries is too low to reduce the TBE burden significantly. 


The authors of “The TBE Book’ therefore have tried to compile in this “working book” the most recent and relevant aspects of TBE. 

 

Atlasītās lappuses

Saturs

1
2a
2b
3
xxx
4
li
5
lxix
6
lxxxix
7
xcviii
12b_Germany
2019
12b_Hungary
2024
12b_Italy
2032
12b_Japan
2039
12b_Kazakhstan
2042
12b_Kyrgyzstan
2049
12b_Latvia
2051
12b_Lithuania
2059

8
cviii
9
cxxv
10
cxlv
11
clvi
12a
18
12b
40
12b_Austria
41
12b_Belarus
63
12b_Belgium
67
12b_Bosnia and Herzegovina
70
12b_Bulgaria
72
12b_China
76
12b_Croatia
49
12b_Czech Republic
54
12b_Denmark
1995
12b_Estonia
2001
12b_Finland
2007
12b_France
2013
12b_Moldova
2064
12b_Mongolia
2066
12b_Netherlands
2066
12b_Norway
2066
12b_Poland
2066
12b_Romania
2066
12b_Russia
2066
12b_Serbia
2066
12b_Slovakia
2066
12b_Slovenia
2066
12b_South Korea
2068
12b_Sweden
2073
12b_Switzerland and Liechtenstein
2081
12b_Ukraine
2088
12c
2091
13
2092
14
2103
Autortiesības

Bieži izmantoti vārdi un frāzes

Par autoru (2019)

Bundeswehr Institute of Microbiology, Munich, Germany

Director Medical and Scientific Affairs, Pfizer Vaccines, Vienna, Austria

Editor, Global Health Press, Singapore / Marburg, Germany

Vice President, Global Lead Viral Vaccines and Clinical Affairs, Pfizer Vaccines, Collegeville, PA, USA Johannes Gutenberg University, Mainz, Germany 

Bibliogrāfiskā informācija